Cerebrospinal fluid D-2-hydroxyglutarate for IDH-mutant glioma monitoring
Neuro-Oncology Advances · 12.01.2026 · 8 (1)
DOI: 10.1093/noajnl/vdag012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 09.03.2026. Verfasst von Cecile Riviere-Cazaux und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, Mayo Clinic, Rochester. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Background
Imaging-based glioma monitoring is confounded by treatment-related changes. D-2-hydroxyglutarate (D-2-HG), produced by the isocitrate dehydrogenase (IDH) mutation, is detectable in cerebrospinal fluid (CSF), which can be sampled from cranial or lumbar compartments. We evaluated CSF D-2-HG as a serially accessible biomarker for IDH-mutant gliomas, including the optimal compartment for longitudinal sampling.
Methods
Lumbar and cranial CSF samples were collected from patients with IDH-mutant gliomas or IDH-wild-type central nervous system pathologies via surgical field collection, lumbar punctures, and CSF access devices. CSF D-2-HG was quantified via our CLIA-certified gas chromatography mass spectrometry assay.
Results
D-2-HG was significantly higher in cranial than lumbar CSF from IDH-mutant glioma patients. Consistent with low D-2-HG abundance in lumbar CSF, lumbar samples could not discriminate IDH-mutant gliomas from IDH-wild-type lesions. In contrast, cranial CSF D-2-HG was significantly higher in IDH-mutant gliomas than wild-type lesions, providing an adequate baseline for initial evaluations of monitoring capabilities. Across 75 samples from 7 consecutive patients with grade 4 IDH-mutant astrocytomas, serial cranial CSF D-2-HG decreased with cytoreduction, remained unchanged with stable disease, and increased with disease progression, but not pseudoprogression.
Conclusions
Serial cranial CSF D-2-HG shows promise as a monitoring biomarker for IDH-mutant gliomas.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurological Surgery, Mayo Clinic, Rochester.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester.
- Department of Neurology, Mayo Clinic, Rochester.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester.
- Department of Medical Oncology, Mayo Clinic, Rochester.
- Department of Radiology, Mayo Clinic, Rochester.
ORCID-Profile: Cecile Riviere-Cazaux, Paul A Decker, Jeanette E Eckel-Passow, Timothy J Kaufmann, Terry C Burns
Förderung
- NCI NIH HHS
- NINDS NIH HHS
- NIGMS NIH HHS
- NCATS NIH HHS
- National Institute of Health
- NINDS
- Mayo Clinic Center for Individualized Medicine
- Lucius & Terrie McKelvey
Zitieren
APA
Riviere-Cazaux, C., Suzuki, Y., Kizilbash, Z., Laxen, W. J., Lacey, J. M., Wipplinger, T. M., Warrington, A. E., Keough, M. B., Kamga, L. F., Andersen, K. M., Canaday, N., Kosel, M. L., Tortorelli, S., Sener, U., Ruff, M. W., Decker, P. A., Eckel-Passow, J. E., Kizilbash, S. H., Kaufmann, T. J., & Burns, T. C. (2026). Cerebrospinal fluid D-2-hydroxyglutarate for IDH-mutant glioma monitoring. Neuro-Oncology Advances, 8(1). https://doi.org/10.1093/noajnl/vdag012
Vancouver
Riviere-Cazaux C, Suzuki Y, Kizilbash Z, Laxen WJ, Lacey JM, Wipplinger TM, et al. Cerebrospinal fluid D-2-hydroxyglutarate for IDH-mutant glioma monitoring. Neuro-Oncology Advances. 2026;8(1). doi:10.1093/noajnl/vdag012
BibTeX
@article{RiviereCazaux2026,
author = {Riviere-Cazaux, Cecile and Suzuki, Yuta and Kizilbash, Zain and Laxen, William J and Lacey, Jean M and Wipplinger, Tamara M and Warrington, Arthur E and Keough, Michael B and Kamga, Lionel Fotso and Andersen, Katherine M and Canaday, Nicholas and Kosel, Matthew L and Tortorelli, Silvia and Sener, Ugur and Ruff, Michael W and Decker, Paul A and Eckel-Passow, Jeanette E and Kizilbash, Sani H and Kaufmann, Timothy J and Burns, Terry C},
title = {Cerebrospinal fluid D-2-hydroxyglutarate for IDH-mutant glioma monitoring},
journal = {Neuro-Oncology Advances},
year = {2026},
volume = {8},
number = {1},
doi = {10.1093/noajnl/vdag012}
}
EUVIMED